Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats

Abstract

Nonsteroidal anti-inflammatory (NSAI) drugs are the most commonly used group of drugs today. Increase in the use of standard NSAI for treating pain and inflammation was restricted by the fact that these drugs were proven to possibly cause gastrointestinal and renal toxicity. Meloxicam is a NSAI that has anti-inflammatory, analgesic, and antipyretic effects. This study aims to investigate the effects of meloxicam on stomach, kidney, and liver of rats under light microscopy level. Based on the light microscopic observations, mononuclear cell infiltration and pseudolobular formation was established in liver samples of animals in the experimental group. Metaplasia in surface and glandular epithelia and atrophy were observed in stomach samples. Glomerular stasis-related hypertrophy and focal interstitial nephritis were found in kidneys. It was concluded in this study that meloxicam might cause hepatotoxicity, nephrotoxicity, and gastric metaplasia in rats at a used dose and duration.

New metallophamaceutic reduced renal injury induced by non-steroidal anti-inflammatory

“…In this study, Wistar rats that received exclusively meloxicam showed renal histological changes (basal membrane thickening and tubulointerstitial nephritis), which are in agreement with other studies [32][33][34] . On the other hand, rats that received meloxicam associated with nitrosyl ruthenium did not present such histological alterations and this is our main result.…”

Meloxicam induced toxicopathology studies in Wistar rats

“…Baggaley et al (2010) reported that animals dosed with meloxicam showed tubular degeneration of kidneys with hemorrhage and oedema due to decreased aquaporin-2 protein water channel expression in renal medulla after oral administration of Indomethacin and Meloxicam. Similar lesions like Glomerular stasis-related hypertrophy and focal interstitial along with the hyperemia were observed in peritubular capillaries in animals which were treated with 15mg/ kg B.W of meloxicam for 15 days (Burukoglu et al,2014). Al-Rekabi et al (2009) concluded that 2.5 million people will be affected by renal damage due to NSAIDs usage.…”

Development of effervescent medical powder containing Maytenus ilicifolia extract Mart. ex Reissek for treatment of gastric disorders

“…It is generally accepted that gastric ulcer is established when the balance between aggressive and mucosal defending factors is disrupted. 2 The Ulcer is a deep lesion of the gastric mucosa that affects the components of epithelial and connective tissue, including subepithelial myofibroblasts, smooth muscle cells, vessels, and nerves. Such ulcerative lesions can be acute or chronic and most often appear in any portion of the gastrointestinal tract exposed to the aggressive action of peptic acid.…”